These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 2512938)
1. Suppression of alimentary lipemia in man by a prostaglandin analogue (enprostil). Schwartz KE; Saito T Atherosclerosis; 1989 Oct; 79(2-3):231-6. PubMed ID: 2512938 [TBL] [Abstract][Full Text] [Related]
2. Suppression of postprandial glucose, insulin, C-peptide, and glucose-dependent insulinotropic peptide (GIP) in man by oral administration of a prostaglandin analogue (enprostil). Schwartz KE; Zaro B; Reynolds J; Duffy J; Saito T; Hunt JS; Sevelius H Horm Metab Res; 1988 Oct; 20(10):637-40. PubMed ID: 3146539 [TBL] [Abstract][Full Text] [Related]
3. Effect of enprostil on gastric emptying, intestinal transit time and post-prandial release of gastro-intestinal peptides. Nicholl CG; Carolan G; Sevelius H; Bloom SR Digestion; 1989; 43(1-2):47-55. PubMed ID: 2509267 [TBL] [Abstract][Full Text] [Related]
4. Enprostil, a synthetic prostaglandin E2 analogue, inhibits meal-stimulated gastric acid secretion and gastrin release in patients with duodenal ulcer. Thomas FJ; Koss MA; Hogan DL; Isenberg JI Am J Med; 1986 Aug; 81(2A):44-9. PubMed ID: 3092654 [TBL] [Abstract][Full Text] [Related]
5. Effects of four orally administered analogues of prostaglandin E1 and E2 on glucose tolerance and on the secretion of pancreatic and gastrointestinal hormones in man. Nauck M; Härter S; Ebert R; Creutzfeldt W Eur J Clin Invest; 1989 Jun; 19(3):298-305. PubMed ID: 2509214 [TBL] [Abstract][Full Text] [Related]
6. Reduction of serum lipoproteins in man by the oral administration of a prostaglandin analogue (enprostil). Schwartz KE; Zaro B; Burton P; Hunt J; Pennelly L; Sevelius H Atherosclerosis; 1988 May; 71(1):9-16. PubMed ID: 3132181 [TBL] [Abstract][Full Text] [Related]
7. A synthetic prostaglandin E2 analogue, enprostil, hastens gastric emptying of solids in patients with an active duodenal ulcer. Nowak A; Jonderko K; Nowakowska-Duława E; Adamczak D; Rudzka J; Nowak S Scand J Gastroenterol; 1990 Nov; 25(11):1118-22. PubMed ID: 2125742 [TBL] [Abstract][Full Text] [Related]
8. Effect of enprostil on glucose and lipid metabolism in type 2 diabetes. Davis TM; Proby C; Strong JA; Thompson GR; Massey H; Scott R; Bloom SR Diabet Med; 1989 Jul; 6(5):400-5. PubMed ID: 2527675 [TBL] [Abstract][Full Text] [Related]
9. Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men. Matikainen N; Björnson E; Söderlund S; Borén C; Eliasson B; Pietiläinen KH; Bogl LH; Hakkarainen A; Lundbom N; Rivellese A; Riccardi G; Després JP; Alméras N; Holst JJ; Deacon CF; Borén J; Taskinen MR PLoS One; 2016; 11(1):e0145890. PubMed ID: 26752550 [TBL] [Abstract][Full Text] [Related]
10. Effect of enprostil on plasma glucose, insulin and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Reaven GM; Swislocki AL; Jeng CY; Hollenbeck CB; Schwartz K; Chen YD Horm Metab Res; 1988 Oct; 20(10):633-6. PubMed ID: 3146538 [TBL] [Abstract][Full Text] [Related]
11. Enprostil. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease. Goa KL; Monk JP Drugs; 1987 Nov; 34(5):539-59. PubMed ID: 3121276 [TBL] [Abstract][Full Text] [Related]
12. Antisecretory effect of a PGE2 derivative, enprostil (TA/RS-84135): inhibitory action of amogastrin-stimulated secretion. Kohli Y; Katoh T; Suzuki K Drugs Exp Clin Res; 1988; 14(11):673-8. PubMed ID: 3149933 [TBL] [Abstract][Full Text] [Related]
13. Reduction by enprostil of aspirin-induced blood loss from human gastric mucosa. Hawkey CJ; Simpson G; Somerville KW Am J Med; 1986 Aug; 81(2A):50-3. PubMed ID: 3092655 [TBL] [Abstract][Full Text] [Related]
14. Inhibitory action of enprostil (4,5-dehydro-16-phenoxy-17,18,19,20-tetranor-PGE2) on tetra-gastrin stimulated acid secretion in human subjects. Moriga M; Aono M; Narusawa H; Kohli Y; Kato T; Kajiyama G; Inoue M; Miyoshi A Gastroenterol Jpn; 1989 Apr; 24(2):115-9. PubMed ID: 2501133 [TBL] [Abstract][Full Text] [Related]
15. Acute and chronic effects of oral enprostil, a synthetic dehydroprostaglandin E2, on uterine contractility. Pulkkinen MO Prostaglandins Leukot Essent Fatty Acids; 1989 Apr; 36(1):15-9. PubMed ID: 2500670 [TBL] [Abstract][Full Text] [Related]
16. Specificity of PGE2 analogs interaction between food intake and antisecretory effect. Levine RA; Petokas S; Czarny L; Schwartz GJ; Bynum L Prostaglandins Leukot Med; 1986 Oct; 24(2-3):219-25. PubMed ID: 3099313 [TBL] [Abstract][Full Text] [Related]
17. Antroduodenal motility studied by real-time ultrasonography. Effect of enprostil. Hausken T; Odegaard S; Berstad A Gastroenterology; 1991 Jan; 100(1):59-63. PubMed ID: 1898497 [TBL] [Abstract][Full Text] [Related]
18. Oral prostaglandin E analogues induce intestinal migrating motor complexes after a meal in dogs. Evidence for a central mechanism. Staumont G; Fioramonti J; Frexinos J; Bueno L Gastroenterology; 1990 Apr; 98(4):888-93. PubMed ID: 2107114 [TBL] [Abstract][Full Text] [Related]
19. Antisecretory and serum gastrin lowering effect of enprostil in patients with duodenal ulcer disease. Mahachai V; Walker K; Sevelius H; Thomson AB Gastroenterology; 1985 Sep; 89(3):555-61. PubMed ID: 3926591 [TBL] [Abstract][Full Text] [Related]
20. Effect of enprostil, a synthetic prostaglandin E2 on 24 hour intragastric acidity, nocturnal acid and pepsin secretion. Deakin M; Ramage J; Paul A; Gray SP; Billings J; Williams JG Gut; 1986 Sep; 27(9):1054-7. PubMed ID: 3093317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]